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Abstract: Peripheral blood as a surrogate tissue for transcriptome proﬁ  ling holds great promise for the discovery of diagnostic 
and prognostic disease biomarkers, particularly when target tissues of disease are not readily available. To maximize the 
reliability of gene expression data generated from clinical blood samples, both the sample collection and the microarray 
probe generation methods should be optimized to provide stabilized, reproducible and representative gene expression proﬁ  les 
faithfully representing the transcriptional proﬁ  les of the constituent blood cell types present in the circulation. Given the 
increasing innovation in this ﬁ  eld in recent years, we investigated a combination of methodological advances in both RNA 
stabilisation and microarray probe generation with the goal of achieving robust, reliable and representative transcriptional 
proﬁ  les from whole blood. To assess the whole blood proﬁ  les, the transcriptomes of puriﬁ  ed blood cell types were measured 
and compared with the global transcriptomes measured in whole blood. The results demonstrate that a combination of 
PAXgene
TM RNA stabilising technology and single-stranded cDNA probe generation afforded by the NuGEN Ovation RNA 
ampliﬁ  cation system V2
TM enables an approach that yields faithful representation of speciﬁ  c hematopoietic cell lineage 
transcriptomes in whole blood without the necessity for prior sample fractionation, cell enrichment or globin reduction. 
Storage stability assessments of the PAXgene
TM blood samples also advocate a short, ﬁ  xed room temperature storage time 
for all PAXgene
TM blood samples collected for the purposes of global transcriptional proﬁ  ling in clinical studies.
Keywords: biomarkers, whole blood, globin reduction, paxgene
TM, NuGEN
TM
Introduction
Development of high-quality biomarkers for disease progression, target engagement, pharmacodynamic 
effects and compound efﬁ  cacy is central to translational research efforts aimed at establishing person-
alised medicine. However, identiﬁ  cation of such biomarkers is frequently hampered by lack of access 
to target tissues with direct biological involvement. As such, peripheral blood (PB) has become an 
increasingly attractive source of surrogate material in place of target tissue as a focus for biomarker 
discovery and application, representing one of the most widely available and practical sources of 
biological material collected within the clinic and permitting a largely non-invasive method of repeated 
analyses within the same patient (Burczynski and Dorner, 2006).
In diseases such as autoimmune disorders and leukaemias, where PB lineages are directly involved 
in the disease process, disease-associated transcriptional proﬁ  les have been well established (Alizadeh 
et al. 2000; Baechler et al. 2003; Bullinger et al. 2004; Crow and Wohlgemuth, 2003; Golub et al. 1999; 
Han et al. 2003; Maas et al. 2002; McLean et al. 2004; Moos et al. 2002; Nowicki et al. 2003; Valk 
et al. 2004; Bennett et al. 2003). In recent years interest has also turned to the potential of PB as a 
surrogate tissue for the discovery of additional types of biomarkers in other scenarios. Given the highly 
dynamic cellular nature of the blood and its circulation throughout the body, it is likely that systemic 
responses to a disease state can be captured within the PB transcriptome. Several examples of successful 
biomarker discovery in transcriptome data derived from PB to date have been reported from pilot studies 
in neurological disorders (Borovecki et al. 2005; Hershey et al. 2004; Tang et al. 2005; Moore et al. 
2005), oncology settings (Twine et al. 2003; Burczynski et al. 2005), SARS (Yu et al. 2005) and 404
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gastrointestinal disorders (Burczynski et al. 2006). 
This accumulating body of evidence supports the 
utility of peripheral blood transcriptional proﬁ  ling 
for identiﬁ  cation of biomarkers that may function 
as biomarkers of disease, evidence of pharmaco-
dynamic effect, or even predictors of clinical 
outcomes and risk of toxicity. Whilst peripheral 
blood transcriptional proﬁ  ling appears to hold great 
promise, there are several limitations to use of this 
matrix for gene expression studies that should be 
carefully considered in any study for resulting 
disease of pharmacodynamic biomarkers to hold 
any clinical utility (Mohr and Liew, 2007).
Transcriptional profiling from PB can be 
achieved using a number of methodologies and 
associated workﬂ  ows; for example a) whole blood, 
b) enriched mononuclear fractions (PBMCs) or c) 
selected/enriched speciﬁ  c hematopoietic lineages. 
Naturally, each of these approaches possess distinct 
advantages and disadvantages. Hematopoietic 
lineage representation in PBMCs or selected/
enriched fractions, whilst not requiring introduc-
tion of globin reduction strategies prior to 
microarray experiments, is naturally restricted to 
the lineages under study and several cell lineages 
are consequently omitted from further analysis. 
Global proﬁ  ling of whole blood RNA, although 
preferable in order to capture the blood transcrip-
tome in its entirety, has traditionally required 
globin reduction strategies prior to probe genera-
tion for microarray analysis in order to reduce the 
interference of globin transcripts with array probes. 
In addition to increasing processing steps, these 
procedures add the risk of artefactual modulation 
of the transcriptome and the utility of globin reduc-
tion strategies have been questioned in several 
reports (Liu et al. 2006; Li et al. 2008; Dumeaux 
et al. 2008).
The consistency of gene expression proﬁ  ling 
data of whole blood is highly dependant on the 
sample stabilisation method used at phlebotomy 
or during storage (Debey et al. 2006; Rainen et al. 
2002). Technologies for whole blood sample 
collection and storage exist, designed in an attempt 
to overcome problems associated with clinical 
collection and PB transcriptome stability. One 
of these, the PAXgene
TM Blood RNA system 
(PreAnalytiX, Hornbrechtikon, Switzerland) 
consists of an evacuated PAXgene
TM RNA tube for 
blood collection and a processing kit for isolation 
of total RNA from whole blood. The PAXgene
TM 
collection tube contains a proprietary reagent that 
is reported to immediately stabilise intracellular 
RNA for up to 3 days at room temperature. The 
potential to minimize the requirement for urgent 
sample processing by increasing the clinical 
sample transcriptome stability in this matrix is 
central to the discovery of robust biomarkers.
Several groups have demonstrated the impact 
of PAXgene
TM blood collection on RNA transcript 
stabilisation using quantitative PCR (qPCR) 
analyses. These studies have demonstrated the 
utility of the PAXgene
TM system in restricting both 
initial and longer term (several days) ex vivo gene 
expression changes occurring after phlebotomy 
compared to conventional anticoagulant methods 
for blood collection (Muller et al. 2002; Pahl and 
Brune, 2002; Rainen et al. 2002; Thorn et al. 2005). 
The impact of different PAXgene
TM storage 
protocols on RNA quantity and quality has also 
been investigated with several reports obtaining 
high quality RNA samples over a range (2 hrs, 
9 hrs, 24 hrs and 5 days) of storage times at room 
temperature (Chai et al. 2005; Thach et al. 2003; 
Wang et al. 2004). When generating gene expres-
sion data using qPCR of selected transcripts as the 
biological readout, good comparisons between 
replicate samples has been shown, although vari-
ability between samples increases with longer 
incubation periods (Wang et al. 2004). Gene 
expression levels of a limited number of transcripts 
in PAXgene
TM-collected whole blood following 
5 days room temperature storage have shown no 
alteration (Chai et al. 2005) compared to 24 hour 
storage. Conversely, a reduction in RNA integrity 
after storage in PAXgene
TM at room temperature 
from 1 to 7 days has been reported and, even 
without apparent reduction in RNA integrity, 
speciﬁ  c transcript instability has been reported 
even with storage at + 4 
oC rather than room 
temperature (Kagedal et al. 2005). Considering the 
potential clinical impact of obtaining high quality 
and faithful gene expression proﬁ  ling from periph-
eral blood, it is crucial to establish a consistent, 
robust and practical sample collection method for 
clinical blood samples.
Due to the high level of reticulocytes in peripheral 
blood there is a predominance of globin mRNA 
transcripts with the potential to (a) result in 
under-representation of non-globin transcripts and 
(b) impact on microarray data quality as a result of 
extensive non-specific cross-hybridisation to 
non-globin probes reducing visualisation of 
non-globin transcripts. Therefore, the quality and 405
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accuracy of gene expression proﬁ  les obtained from 
peripheral blood is highly reliant on the effectiveness 
of globin reduction carried out prior to microarray 
probe generation. Technologies available to reduce 
globin mRNA have been shown to efficiently 
increase the sensitivity of transcript detection (Field 
et al. 2007; Li et al. 2008; Liu et al. 2006) but can 
also reduce the signal intensities achieved for some 
genes (Field et al. 2007). Importantly, methods of 
globin reduction have also been shown to introduce 
changes in the transcriptome profile observed 
(Feezor et al. 2004; Liu et al. 2006). A potential 
solution to the problem of globin reduction prior to 
gene expression proﬁ  ling of whole blood has been 
launched by NuGEN Technologies
TM (California, 
U.S.A.) in the form of the Ovation
TM RNA ampli-
ﬁ  cation system V2. The Ovation system utilises a 
single primer, isothermal linear ampliﬁ  cation (SPIA) 
method (Kurn et al. 2005) to generate single-strand 
cDNA microarray probes suitable for use with 
Affymetrix GeneChips
TM. Reproducibility studies 
and comparison to other microarray methods have 
illustrated a high degree of consistence and greater 
hybridisation speciﬁ  city when exploiting sscDNA:
DNA hybridisation compared to cRNA:DNA on 
microarrays (Barker et al. 2005). The NuGEN
TM 
Ovation Whole Blood System does not require 
globin reduction strategies. Whilst globin transcripts 
are still converted to ssDNA, the high abundance 
of these do not present an issue in microarray hybri-
disations due to the increased speciﬁ  city of sscDNA 
probes compared to cRNA probes. This system 
therefore has the potential to allow whole blood 
transcriptional proﬁ  ling with decreased sample 
processing steps and circumvention of potential 
artefactual modulation of the transcriptome associ-
ated with globin reduction strategies. Ultimately, 
the utility of any whole blood proﬁ  ling approach is 
dependent on its ability to provide a faithful repre-
sentation of the individual hematopoietic lineage 
transcriptomes present in blood.
In the present study we therefore sought 
to identify a workﬂ  ow which potentially allows 
(a) efﬁ  cient and immediate stabilisation of collected 
peripheral whole blood and (b) microarray probe 
generation without the requirement for globin 
reduction. In addition to establishing the robustness 
and reproducibility of such methods, we also 
gauged the representation of speciﬁ  c hematopoietic 
lineage transcriptomes afforded by the evaluated 
approaches in order to identify an optimal 
workﬂ  ow.
Materials and Methods
Sample collection and processing
Blood samples were collected from an appropriately 
consented healthy donor using the PAXgene
TM 
collection tube system (PreAnalytiX, Hornbrechtikon, 
Switzerland). Blood was drawn by standard 
phlebotomy procedures, with 2.5 ml dispensed into 
each of 6 PAXgene
TM  tubes and processed according 
to the manufacturer’s directions (Fig. 1). Brieﬂ  y, half 
of the samples collected (n = 3) were maintained at 
room temperature for 2 hrs and the other half for 
PAX’ PAX’ PAX’ PAX’ PAX’ PAX’
Experiments 1 + 2
Donor A
15 ml fresh  blood  
2.5 ml
Inverted 10X Inverted 10X
2 hrs @ RT 24 hrs @ RT
–20ºC o/n
–80ºC 
Thaw for 2 hrs @ RT 
PAXgene WB RNA isolation
NuGENTM WB SPIA sscDNA amplification
6 X HG U133 Plus  2.0 arrays
Figure 1. Experiment workflow utilised for storage and 
processing of PAXgene
TM-collected whole blood. Peripheral whole 
blood was collected from a single donor on each of two separate days 
(Experiments 1 and 2). 2.5 ml whole blood was dispensed in each of 
6 PAXgene
TM tubes for each experiment. Following inversion 
(10 times), tubes were stored at room temperature for 2 hrs or 24 hrs. 
All samples were then transferred to −20 
oC overnight followed 
by −80 
oC for storage until RNA isolation procedures were performed 
using the PAXgene
TM RNA isolation kit. sscDNA probes were synthe-
sised by NuGEN Whole Blood SPIA ampliﬁ  cation using the NuGEN 
Ovation
TM RNA ampliﬁ  cation V2 and Whole Blood reagent system. 
sscDNA was then hybridised to Affymetrix Human Genome U133 
Plus 2.0 arrays. WB—Whole Blood, HG = Human Genome, 
PAX’ = PAXgene
TM and RT = Room Temperature.406
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24 hrs, both within the manufacturers’ stated period 
of storage stability of 2–72 hrs. All samples were 
inverted 10 times and frozen at −20 
oC overnight and 
then moved to −80 
oC for storage until RNA isolation 
(Experiment 1). This same experimental procedure 
was repeated using a fresh blood draw obtained from 
the same donor on a separate day (Experiment 2).
Additional blood samples from the same subject 
were collected into K3-EDTA tubes and processed 
for full blood counts on a Sysmex XE 2100 fully 
automated full blood count analyser.
Total RNA isolation
Frozen PAXgene
TM tubes were thawed at room 
temperature for 2 hours followed by total 
RNA isolation according to the manufacturers’ 
instructions (PreAnalytiX, Hornbrechtikon, 
Switzerland). Brieﬂ  y, PAXgene
TM blood tubes 
were centrifuged for 10 minutes at 3000 × g, the 
supernatant removed and the cell pellet resus-
pended in 4 ml of RNase-free water. Samples 
were re-centrifuged for 10 minutes at 3000 × g 
and the supernatant removed. The cell pellet was 
resuspended in 350 μl Buffer BR1 and following 
the addition of 300 μl Buffer BR2 and 40 μl 
Proteinase K incubated for 10 minutes at 55 
oC 
while shaking at 400 rpm. The resultant lysate 
was centrifuged through a PAXgene
TM Shredder 
spin column at 16,300 × g for 3 minutes. 
The supernatant of the ﬂ  ow through was added 
to 350 μl of 100% ethanol, mixed and applied 
to a PAXgene
TM RNA spin column and centri-
fuged for 1 minute at 16,300 × g. 350 μl of 
Buffer BR3 was added to the PAXgene
TM RNA 
spin column and centrifuged for 1 minute at 
16,300 × g. A DNase I incubation mix was 
prepared by combining 10 μl of DNase I and 
70 μl of Buffer RDD per sample. DNase treat-
ment was performed by pipetting 80 μl of DNase 
I incubation mix directly on to the PAXgene
TM 
RNA spin column membrane and incubating at 
room temperature for 15 minutes. To wash the 
PAXgene
TM RNA spin column 350 μl of Buffer 
BR3 was added and centrifuged for 1 minute at 
16,300 × g. 500 μl of Buffer BR4 was added 
to the PAXgene
TM RNA spin column and 
centrifuged for 1 minute at 16,300 × g. The 
addition of Buffer BR4 was repeated with a 
3 minute 16,300 × g centrifugation followed 
by additional centrifugation for 1 minute at 
16,300 × g to dry the column. RNA was eluted 
into a fresh 1.5 ml microcentrifuge tube using 
40 μl of Buffer BR5 followed centrifugation for 
1 minute at 16,300 × g. Elution was repeated with 
40 μl of fresh Buffer BR5 giving a total elution 
volume of 80 μl. Eluted RNA was denatured for 
downstream applications by incubation at 65 
oC 
for 5 minutes. Total RNA concentration was 
measured by Nanodrop ND-8000 (Nanodrop 
Technologies, Wilmington, DE, USE), and the 
integrity of the extracted total RNA was assessed 
using RNA Nano Chips on an Agilent 2100 
Bioanalyzer (Agilent Technologies, Santa Clara, 
CA, U.S.A). Agilent Bioanalyzer 2100 electro-
pherograms were analysed by the Biosizing 
software 2100 Expert Version B.02.03.SI307 
(Agilent Technologies, 2100 Bioanalyzer) to 
generate RNA integrity numbers (RIN) as an 
RNA quality control metric.
Hematopoietic cell lineages
Hematopoietic cell lineage transcript expression 
data was obtained from a number of sources 
(see Table 4). RNA derived in-house (B-cells, 
T-cells and Dendritic cells) for microarray hybri-
disation was obtained from frozen cell preparations 
purchased from Lonza Biosciences (Basel, 
Switzerland). Transcript expression data for a wide 
range of other cell lineages were obtained from 
public datasets deposited in the Gene Expression 
Omnibus (http://www.ncbi.nlm.nih.gov/geo/), 
accession numbers GSE1133 and GSE3982 
(Jeffrey et al. 2006; Su et al. 2004). Taken together 
this dataset provided a source of mRNA expres-
sion data (derived from Affymetrix GeneChips
TM) 
from a wide range of hematopoietic cell lineages 
prepared by either density gradient, positive or 
negative paramagnetic bead isolation, and with or 
without stimulated differentiation in vitro.
Microarray probe generation
Preparation of single stranded cDNA (sscDNA) 
SPIA probes for microarray hybridisation, without 
the requirement for globin reduction pretreatment, 
was carried out with 50 ng of total PAXgene
TM 
RNA using NuGEN Technologies (California, 
U.S.A.) Ovation
TM RNA amplification system 
V2 according to the manufacturers’ instructions. 
Synthesised sscDNA probe concentration was 
measured by Nanodrop ND-8000 (Nanodrop 
Technologies, Wilmington, DE, U.S.A). The 
NuGEN Technologies FL-Ovation
TM cDNA Biotin 407
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Module V2 was used for sscDNA fragmentation 
and biotin labelling of 4.4 μg of the ampliﬁ  ed 
sscDNA for subsequent hybridisation to the micro-
arrays (Affymetrix, Santa Clara, CA, U.S.A). The 
quality of the sscDNA probes was assessed before 
and after fragmentation with the Agilent 2100 
Bioanalyzer using RNA Nano chips (Agilent 
Technologies, Santa Clara, CA, U.S.A).
RNA (2 μg) prepared in-house from B-cells, 
T-cells and Dendritic cells was converted to cRNA, 
further processed according to Affymetrix (Santa 
Clara, CA, U.S.A) recommendations and quality 
assessed by Agilent 2100 Bioanalyser.
Nanodrop ND-8000 and Agilent 2100 Bioanalyzer 
were also utilised for concentration and quality 
assessment of sscDNA generated by NuGEN 
Ovation
TM RNA ampliﬁ  cation system V2 (Table 1, 
Fig. 2).
Affymetrix GeneChips
For in-house prepared B-cell, T-cell and dendritic 
cell data, 15 μg of fragmented cRNA was hybri-
dised to Affymetrix HG-U133A GeneChips, 
according to standard Affymetrix procedures. Data 
from GSE1133 and GSE3982 also resulted from 
hybridisation to HG-U133A GeneChips.
sscDNA probes generated from RNA isolated 
from PAXgene
TM collected blood were hybridised 
to Affymetrix Human Genome U133 Plus 2.0 
Arrays (Affymetrix, Santa Clara, CA, U.S.A.) as 
described in the Affymetrix Expression Analysis 
Technical Manual. Brieﬂ  y, 4.4 μg of fragmented 
and labelled sscDNA, together with spiked hybri-
disation controls (GeneChip Expression 3’ Ampli-
ﬁ  cation Reagents—hybridisation controls), was 
hybridised for 18 hrs at 45 
oC in a rotating oven. 
Following hybridisation GeneChip washing and 
staining was performed using the GeneChip 
Hybridisation Wash and Stain kit (Affymetrix, 
Santa Clara, CA, U.S.A.) on an Affymetrix 
GeneChip Fluidics Station 450 using the appropri-
ate ﬂ  uidic script for the U133 Plus 2.0 microarrays 
with sscDNA (FS450-0004). GeneChips were 
scanned immediately following staining in an 
Affymetrix GeneChip Scanner 3000 (Affymetrix, 
Santa Clara, U.S.A).
Data analysis
Report ﬁ  les summarising the quality of target and 
control detection for each microarray were 
generated by GeneChip Operating Software 
Version 1.4 (GCOS) using the MAS5.0 algorithm 
(Affymetrix, Santa Clara, CA, U.S.A). All 
parameters (noise factor, background, and scaling 
factor) were acceptable by Affymetrix recommen-
dations (Table 2).
Assessment of PAXgene
TM / NuGEN
TM sscDNA 
whole blood data was performed using a combina-
tion of Affymetrix MAS5.0 feature extraction and 
RMA (Irizarry et al. 2003). Brieﬂ  y, those probesets 
determined by MAS5.0 to be present in at least 
25% of the PAXgene
TM whole blood samples were 
selected for downstream analyses. Array ﬁ  les were 
subsequently processed by RMA, filtered on 
those MAS5.0-selected probesets. Data were 
Log2-transformed and those probesets with values 
greater than 6.5 in at least one sample selected for 
further analysis. Comparison between 2 hrs and 
24 hrs PAXgene
TM storage was performed by SAM 
analysis (Tusher et al. 2001) implemented in TM4 
MEV (multi-experiment viewer) (Saeed et al. 2003) 
and using all samples, from both experiments 
1 and 2 together, with a False Discovery Rate (FDR) 
of 0.05.
Table 1. Yield and quality metrics for isolated total RNA and synthesized single stranded cDNA probes.
Experiment Storage time 
(hours)
RNA yield 
(μg/ml)
Bioanalyser 
RIN
sscDNA yield 
(μg)
12 4.87 + (0.18) 9.0 + (0.06) 9.3 + (0.43)
12 4 5.94 + (0.24) 8.5 + (0.07) 8.9 + (0.27)
22 5.86 + (0.31) 9.3 + (0.03) 8.1 + (0.25)
22 4 4.55 + (0.61) 8.8 + (0.03) 7.7 + (0.10)
Mean quality metrics for total RNA isolated from 2 hrs (n = 3) and 24 hrs (n = 3) stored PAXgene
TM whole blood samples from both experiments 
1 and 2 are indicated. Numbers in parenthesis represent s.e.m. Storage time refers to the period the PAXgene
TM collected whole blood 
samples were stored at room temperature prior to storage at −20 
oC. Room temperature incubations are a model of the period samples 
spend in the clinic or in transit before processing by the appropriate laboratory. RNA quality metrics were obtained by Nanodrop ND-8000 
spectrophotometery and by Agilent 2100 Bioanalyzer. RIN; RNA Integrity Number.408
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For assessment of any 3’ or 5’ bias of probeset 
signal intensity the chromosomal location of probe-
sets were mapped from Affymetrix NetAffx anno-
tation, allowing assessment of bias of signal 
intensity for those transcripts containing two or 
more probesets at distinct positions of the 
corresponding transcript.
To identify probesets most indicative of speciﬁ  c 
hematopoietic lineages, SAM analysis was 
performed with an FDR of 0 to select probesets 
signiﬁ  cantly over-represented in one cell type 
compared to all other cell types within the same 
dataset. Following identification of probesets 
signiﬁ  cantly over-represented in one particular 
lineage we applied a second ﬁ  ltering criterion of 
exclusion of those probesets with linear expression 
levels of less than 200 to maximise the likelihood 
of relevance of identified probesets being 
“diagnostic” of speciﬁ  c hematopoietic lineages.
CEL ﬁ  les for Paxgene
TM data and internally 
generated hematopoietic lineage microarray data 
are available from Array Express (http://www.ebi.
ac.uk/microarray-as/aer), accession number 
E-MEXP-1600.
Results
RNA yield and quality
In order to assess the yield and quality of the RNA 
obtained following PAXgene
TM RNA stabilisation 
and isolation according to the workﬂ  ow outlined 
in Figure 1, quality control analyses were carried 
out and yields are presented in Table 1. Analysis 
of total RNA quality by Agilent Bioanalyzer 
generated showed high RIN (RNA integrity 
numbers) for all samples (Table 1), revealing good 
quality RNA above the level traditionally deemed 
acceptable for microarray probe generation 
(RIN = 7.0) (Fig. 2, A). No signiﬁ  cant differences 
in yield or quality of RNA obtained from samples 
collected (a) in different experiments or (b) as a 
result of PAXgene
TM storage time were noted.
Efﬁ  cacy of sscDNA probe preparation 
from PAXgene
TM whole blood RNA
All RNA samples were used to synthesize sscDNA 
probes for use in microarray gene expression 
profiling. Yields of sscDNA within the same 
experiments are tightly grouped and no signiﬁ  cant 
difference between experiments or as a result of 
incubation times were observed (Table 1). sscDNA 
yields were consistently in excess of the 4.4 μg 
required for further processing for array hybridi-
sations. Quality assessment by Agilent Bioanalyzer 
shows that the sscDNA fragments generated from 
whole blood RNA are of broad distribution in 
length, averaging approximately 1000 nucleotides, 
suggesting efﬁ  cient sscDNA synthesis (Fig. 2, B). 
sscDNAs were fragmented and biotin-labelled in 
preparation for hybridisation and all resulted in 
fragments of ~50–200 nt (data not shown), similar 
to results previously reported using this method 
(Barker et al. 2005).
Quality of microarray measurements
High quality control metrics for both RNA and 
sscDNA indicated successful sample preparation 
and all were subsequently hybridised to Affymetrix 
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Figure 2. Bioanalyser electropherograms of total RNA isolated 
from PAXgene
TM collected whole blood and subsequently 
synthesised sscDNA probes. (a) Bioanalyzer electropherograms 
of a representative RNA from each experimental group are shown. 
(b) sscDNA quality assessed by distribution of size. The majority 
of sscDNA synthesised is in the order of approximately 1000 nucle-
otides. Bioanalyzer electropherograms of a representative sscDNA 
from each experimental group are shown. x-axis represents 
nucleotide length and y-axis is arbitrary signal intensity ﬂ  uorescence 
units.409
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Human Genome U133 Plus 2.0 Arrays. All arrays 
within the study generated percentage present calls 
of between 60%–63%. Average background was 
32.80 + 0.31 (mean + standard error), within the 
typical range of 20–100, the average noise factor 
was 1.43 + 0.04 and the average scaling factor for 
all arrays was 1.56 + 0.08. Finally, the β-actin 
3’–5’ ratio were consistent between all arrays 
suggesting no signiﬁ  cant degradation of samples. 
Neither experiment or incubation period of 
PAXgene
TM whole blood contributed to any 
variation in quality control metrics (Table 2).
Hematopoietic transcriptome stability 
in PAXgene
TM Whole Blood samples
Following data normalisation, transformation and 
ﬁ  ltering, as outlined in materials and methods, 
Principal Component Analysis of remaining 
probesets was performed (Fig. 3a). As would be 
expected, distinct groupings of data according to 
experimental day were evident. Similarly, the 
PCA model revealed significant influence of 
PAXgene
TM whole blood incubation period to 
variance within the dataset, for both experiments. 
SAM analysis was used with an FDR of 0.05 to 
identify those probesets differing in expression 
level in PAXgene
TM whole blood samples stored 
at 24 hrs relative to 2 hrs. Those probesets 
fulﬁ  lling these criteria and which differ in expres-
sion level greater than 1.5-fold in 24 hr samples 
relative to 2 hrs are represented graphically in 
Figure 3b. This analysis identified a total of 
3311 probesets differentially represented in 
PAXgene
TM collected whole blood incubated at 
room temperature for 24 hrs compared to 2 hrs. 
The vast majority of these, 3050 (92.1%), 
represent probesets with lower signal intensities 
in 24 hr relative to 2 hr samples. Whilst a large 
amount of these (78.6%) are relatively modest 
1.5 to 2-fold changes, a signiﬁ  cant number are 
differentially represented at levels greater than 
2-fold, with only 4 of these representing probesets 
over-represented in 24 hr samples. The complete 
annotated list of these probesets is available as 
Supplementary online Table 1.
We ﬁ  rst considered the possibility whether those 
probesets under-represented in 24 hr samples were 
indicative of canonical degradation of mRNAs. 
To assess whether these could be due to 5’−3’ 
degradation of the mRNA transcripts we exploited 
the fact that several transcripts are represented by 
2 or more probesets on the Affymetrix Human 
Genome U133 Plus 2.0 Arrays. The Affymetrix 
annotation ﬁ  le allows us to map the chromosomal 
location of these multiple probesets for the genes 
showing differential expression between 2 hrs and 
24 hrs storage. This then allowed identiﬁ  cation of 
which probeset is responsible for reduced signal 
intensity in the 24 hrs samples and subsequent 
assessment of whether this was due to a loss of the 
3’ or 5’ probesets. Most genes were excluded from 
Table 2. Quality metrics following hybridisation of sscDNA probes generated from whole blood RNA to Affymetrix 
Human Genome U133 Plus 2.0 Arrays.
Experiment Storage time 
(hours)
% 
Present
Mean% 
present
Mean actin 3’5’ 
ratio
Mean GAPDH 3’5’ 
ratio
1 2 62.5
60.8
63
62.1 + (0.64) 2.06 + (0.04) 1.59 + (0.01)
1 24 62.6
63.8
61.7
62.7 + (0.63) 2.23 + (0.08) 1.51 + (0.03)
2 2 62.5
62.9
61.4
62.3 + (0.44) 2.47 + (0.13) 1.67 + (0.04)
2 24 61.8
60.3
62.4
61.5 + (0.63) 2.52 + (0.20) 1.63 + (0.07)
Mean quality metrics for microarrays from hybridisation of sscDNA generated from PAXgene
TM whole blood RNA stored for 2 hrs (n = 3) and 
24 hrs (n = 3). PAXgene
TM whole blood samples from both experiments 1 and 2 are indicated. Numbers in parenthesis represent s.e.m. 
Quality metrics reﬂ  ect GCOS report data generated following MAS5.0 feature extraction.410
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Figure 3. Analyses of array data derived from hybridisation of sscDNA probes generated from PAXgene
TM collected whole blood 
RNA. (a) Principal Component Analysis of those probesets remaining after ﬁ  ltering for (i) present call by MAS5.0 in at least 25% of samples 
and (ii) signal intensity greater than 6.5 (Log2) in at least one sample following RMA processing of probesets derived from (i). Squares, 
experiment 1; triangles, experiment 2; blue, 2 hrs incubation; red, 24 hrs incubation. (b) Graphical representation of the number of probesets 
determined to be over- or under-represented in 24 hr compared to 2 hr stored samples following SAM analysis with an FDR of 0.05 and fold 
change  1.5. The number of probesets within each fold change range is indicated.411
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these analyses due to the presence of only one 
probeset or multiple probesets mapping to 
overlapping chromosomal regions. In total 
117 transcripts were utilised to investigate a poten-
tial polarity effect (i.e. 3’ or 5’ degradation). 
Interestingly, of these 117 genes a clear degradation 
effect was observed with 94 genes displaying 
preferential loss of a 3’ probeset and only 23 genes 
showing loss of a 5’ probeset suggesting highly 
signiﬁ  cant (P   1 × 10
−7, repeat random sampling) 
3’ degradation.
Faithfulness of hematopoietic cell 
lineage transcriptome representation 
in PAXgene
TM whole blood expression 
proﬁ  les
It is essential that any workﬂ  ow utilising whole 
blood provides a faithful representation of indi-
vidual cell lineage transcriptomes. We wished to 
have an objective measurement of the probesets 
we had identiﬁ  ed as “present” in our PAXgene
TM 
analyses compared to probesets independently 
identiﬁ  ed from samples where speciﬁ  c haemato-
poietic cell lineages had been isolated as being 
indicative of the identity of that particular lineage. 
We pursued this approach with the additional inten-
tion of investigating whether the marked under-
representation of a large number of probesets 
following 24 hr PAXgene
TM whole blood storage 
resulted from preferential reduction in signal inten-
sity of probes accounted for by a particular hema-
topoietic lineage. ‘Signature probe-sets’ indicative 
for a number of individual haematopoietic cell 
lineages were estimated from both in-house and 
public data sets (Jeffrey et al. 2006; Su et al. 2004). 
These datasets were generated utilising a wide 
range of enrichment techniques; positive and/or 
negative selection and with or without in vitro 
stimulation and culture from either cord blood or 
peripheral blood (Table 4). Signature probesets 
were identiﬁ  ed following SAM analysis with an 
FDR of 0, as indicated in materials and methods, 
from those found to be significantly over-
represented in the cell-type of choice, compare to 
all other cell-types in that dataset. This data is 
summarised in Table 4 and the resultant annotated 
list of lineage-enriched probesets are available as 
Supplementary online Table 2.
To safeguard against any differences in 
hematopoietic cell lineages observed between 
our PAXgene dataset and others being due to 
abnormal levels of a particular cell lineage from 
the individual donor used in this study full haema-
topoietic analysis on blood samples from this 
individual was carried out and shown to be within 
healthy boundaries (Table 3).
Probesets determined to be hematopoietic cell 
lineage enriched remain well represented in 
the PAXgene
TM/sscDNA 2 hr/24 hr com-
bined dataset (Table 4, Fig. 4), with several 
reaching 100% representation. Macrophages and 
dendritic cell transcript “signatures” appear 
most-under-represented in the PAXgene
TM/ sscDNA 
whole blood expression data (71% and 75% respec-
tively). Notably, those probesets determined to be 
sensitive to PAXgene
TM whole blood incubation 
period do not appear to be contributed to by any 
particular individual lineage under study. Whilst the 
high degree of representation of individual hema-
topoietic lineage transcriptome in PAXgene
TM / 
sscDNA data was encouraging it was important to 
establish that this was not due solely to high abun-
dance transcripts being interrogated. We therefore 
investigated the relationship between abundance of 
transcripts identiﬁ  ed as being indicative of a par-
ticular lineage compared to transcript abundance 
observed in the PAXgene
TM/sscDNA data (Fig. 4). 
The small number of lineage enriched probesets, 
not represented in the PAXgene
TM/sscDNA dataset, 
appear over a range of abundances but are mostly 
lowly expressed in both the original and PAXgene
TM 
datasets. Importantly, several low abundant genes 
within the isolated cell data sets are robustly 
detected in the PAXgene
TM dataset (Fig. 4). Interest-
ingly, there is a general concordance between the 
Table 3. Donor hematological full blood counts.
Cell type Donor A
RBC (× 10
12/L) 5.3 (4.5–6.0)
WBC (× 10
9/L) 6.3 (4.0–11.0)
Neutrophils (× 10
9/L) 3.4 (2.0–7.5)
Lymphocytes (× 10
9/L) 2.2 (1.5–4.0)
Monocytes (× 10
9/L) 0.4 (0.2–0.8)
Eosinophils (× 10
9/L) 0.25 (0–0.4)
Basophils (× 10
9/L) 0 (0–0.1)
Platelets (× 10
9/L) 198 (150–400)
Full haematological analysis of whole blood samples illustrate that 
all haematopoietic cell lineages are present in concentrations within 
the normal range in donor A. RBC = Red blood cells, WBC = White 
blood cells. Parenthesis = ref. range for males.412
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levels of expression in the original cell-line speciﬁ  c 
data and in our PAXgene
TM whole blood data set.
There is only low representation (0%–2%) of 
any of these lineage speciﬁ  c probesets in those 
determined to be unstable as a result of storage 
times, therefore no loss of a particular cell lineage 
accounts for these changes.
Discussion
The ability to robustly detect and measure bio-
logical variation associated with disease or 
pharmacologic intervention in whole blood clinical 
samples is key to the future discovery of surrogate 
disease biomarkers leading to translational research 
and personalised medicine. To this end we have 
assessed a workﬂ  ow which allows microarray 
gene expression analysis of whole blood using 
PAXgene
TM RNA stabilisation and subsequent 
sscDNA microarray probe generation without the 
requirement for globin reduction practices.
Despite claims that PAXgene
TM technology 
efﬁ  ciently stabilises whole blood samples for up 
Table 4. Source details of hematopoietic cell lineages.
Cell type Dataset Purity Markers Enrichment Positive 
selection 
antibody
Origin
CD19
+ B-Cells In-house  85% CD19 Negative selection n/a Cord blood
CD4
+ T-Cells In-house  90% CD4 Negative selection n/a Peripheral blood
Dendritic Cells In-house  85% CD14, 
CD56
Leukopheresis 
and density 
gradient. In vitro 
differentiation.
n/a Peripheral blood
Eosinophils GSE3982 97% CD16 Percoll gradient n/a Peripheral blood
Macrophages GSE3982 Unknown Unknown Ficoll gradient, 
positive selection, 
GM-CSF
Anti-CD14 Peripheral blood
Neutrophils GSE3982  97% CD16, 
CD62L
Ficoll gradient, 
negative selection
n/a Peripheral blood
B-Cells GSE3982  96% CD19 Ficoll gradient, 
positive selection
Anti-CD19 Peripheral blood
Basophils GSE3982  96% CCR3 Ficoll gradient, 
negative selection 
followed by 
positive selection
Anti-CCR3 Peripheral blood
NK Cells GSE3982  96% CD16, 
CD56
Ficoll gradient, 
positive selection
Anti-CD16/
CD56
Peripheral blood
Immature 
Dendritic Cells
GSE3982 Unknown Unknown Ficoll gradient, 
positive selection, 
IL14/GM-CSF 
differentiation
Anti-CD14 Peripheral blood
CD14
+ 
Monocytes
GSE1133 Unknown CD14 Density gradient 
and positive 
selection
Anti-CD14 Peripheral blood
CD19
+ B-Cells GSE1133 Unknown CD19 Negative selection n/a Peripheral blood
CD4
+/CD8
+ 
T-Cells
GSE1133 Unknown CD4/
CD8
Unknown n/a Peripheral blood
CD56
+ NK 
Cells
GSE1133  90% CD16, 
CD56
Unknown n/a Peripheral blood
Preparation details for datasets utilised for generation of probesets indicative of speciﬁ  c hematopoietic cell lineages are shown for both 
in-house generated data and GSE3982 and GSE1133. Prepared cells are from a variety of sources and derived by a number of methods, 
including positive and negative selection (or both) and with or without in vitro differentiation procedures.413
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Figure 4. Scatterplots indicating the representation of lineage-enriched probesets in PAXgene
TM/sscDNA-derived data.
Log2-transformed expression data for those probesets indicative of speciﬁ  c lineages compared to expression data derived from 
PAXgene
TM/sscDNA hybridisations are indicated. Sources of each dataset are noted. Probesets passing the ﬁ  lters outlined in methods and 
materials but which were determined not to be expressed in the PAXgene
TM/sscDNA datasets are indicated as ﬁ  lled red circles. DCs, dendritic 
cells; NK, Natural killer cells.414
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to 3 days at room temperature, reports of reduced 
RNA quality with longer PAXgene
TM storage and 
importantly, instability of a small number of studied 
transcripts despite retention of RNA integrity 
(Kagedal et al. 2005), within these recommended 
storage limits, warranted further investigation of 
transcriptome stability in PAXgene
TM collected 
whole blood. To assess the stability of the entire 
whole blood transcriptome under storage condi-
tions reﬂ  ecting likely sample collection schema in 
clinical environments and within the recommended 
limits of the PAXgene
TM technology we used 
Affymetrix GeneChip array technology and 
PAXgene
TM collected whole blood stored at room 
temperature for either 2 or 24 hrs.
Our data demonstrate that PAXgene
TM stabilised 
peripheral blood samples stored at room tempera-
ture for either 2 hrs or 24 hrs results in high quality 
RNA and generate ample sscDNA microarray 
probes for gene expression analysis, with subse-
quent arrays being of high quality with signiﬁ  cantly 
high present calls (60%–62%), despite the omission 
of any globin interference reduction strategies. As 
would be expected, further analysis of array data-
sets revealed significant contribution of 
(a) experimental day and (b) incubation period to 
overall variance within the data. However, despite 
the preservation of RNA quality, storage for 24 hrs 
at room temperature resulted in signiﬁ  cant tran-
scriptome alterations compared to storage for 2 hrs, 
Table 5. Representation of probesets indicative of speciﬁ  c hematopoietic cell lineages in the PAXgene
TM whole 
blood / sscDNA dataset.
Cell type Dataset Number 
of 
probesets 
indicative 
of cell 
lineage
Number of cell-
lineage “signature” 
probesets present 
in PAXgene
TM/
sscDNA dataset
Representation of 
cell-lineage 
“signature” 
probesets present 
in PAXgene
TM/
sscDNA dataset 
(%)
Cell lineage 
“signature” 
probesets 
also identi-
ﬁ  ed to be 
storage 
time-
sensitive 
(%)
CD19
+ B-Cells In-house 119 116 97 2.0
CD4
+ T-Cells In-house 34 34 100 3.0
Dendritic Cells In-house 52 39 75 2.0
Eosinophils GSE3982 78 73 94 8.2
Macrophages GSE3982 76 54 71 3.7
Neutrophils GSE3982 365 361 99 4.1
B-Cells GSE3982 62 62 100 4.8
Basophils GSE3982 102 90 88 8.9
NK Cells GSE3982 41 41 100 0
Immature 
Dendritic Cells
GSE3982 56 46 82 0
CD14
+ 
Monocytes
GSE1133 35 35 100 2.9
CD19
+ B-Cells GSE1133 39 38 97 5.3
CD4
+/CD8
+ 
T-Cells
GSE1133 224 209 94 3.4
CD56
+ NK Cells GSE1133 106 99 93 4.0
The number of probesets determined, as outlined in the materials and methods section, to be most indicative of speciﬁ  c hematopoietic cell 
lineages from in-house generated array data and from GSE3982 (Jeffrey et al. 2006) and GSE1133 (Su et al. 2004) are indicated. The 
number or proportion of these present in processed and ﬁ  ltered data derived from hybridisation of sscDNA probes derived from RNA isolated 
from PAXgene
TM collected whole blood are indicated. The number of those probesets for each lineage which were also identiﬁ  ed to be 
incubation period sensitive is also presented. NK cells; Natural Killer Cells.415
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with the majority (92.1%) representing probesets 
under-represented in 24 hr samples at levels greater 
than 1.5-fold. We interpret this to indicate that 
intracellular RNA stabilisation is not 100% com-
plete following 2 hrs storage at room temperature. 
Those transcripts for which we were able to further 
investigate polarity of any degradation effect sub-
stantiated this notion, with significantly lower 
signal intensity being attributed to the 3’ end of 
transcripts. Whilst this in agreement with incom-
plete RNA stabilisation it also indicates that this 
does not necessarily result in canonical RNA deg-
radation, with this data indicating loss of poly(A) 
sequences, the effects of which would of course be 
expected to manifest most profoundly in procedures 
utilising poly(A) tails for reverse transcription. The 
clinical implication of these ﬁ  ndings are signiﬁ  cant 
as variation in sample storage or transportation time 
will lead to ex vivo transcriptome alterations which 
may mask any clinically relevant biological varia-
tion present within those transcripts affected by 
storage artefacts. However, it is important to note 
that Affymetrix expression array GeneChips are 
focussed to the 3’ end of transcripts and this should 
be considered when evaluating our data in context 
with competitor microarray platforms.
Whilst size, nucleotide composition, secondary 
structure properties and abundance of transcripts 
could all conceivably account in part for the stor-
age time dependent transcriptome alterations noted 
here we also considered it possible, albeit unlikely 
after more than 2 hours, that this could indicate 
differential lysis of a particular hematopoietic 
lineage within the PAXgene
TM lysis matrix, thereby 
fostering RNA degradation within those cells. 
Notably, signal intensities of the vast majority 
(74%) of those transcripts identified as being 
PAXgene
TM storage period sensitive at 24 hrs are 
within the upper 50% of signal intensity distribu-
tion for those probesets obtained at 2 hrs (data not 
shown), indicating that increased periods of whole 
blood storage in the PAXgene
TM system predomi-
nantly affects transcripts of highest abundance.
Comparison of our PAXgene
TM sample data set 
with expression data of transcripts determined to be 
indicative of speciﬁ  c lineage populations, we dem-
onstrated that the 24 hr under-represented transcripts 
appeared to be cell-lineage independent. Similarly, 
pathway mapping analysis did not reveal any obvi-
ous networks that could be attributed to cell-speciﬁ  c 
biological functions (data not shown). The 
underlying factors inﬂ  uencing transcript speciﬁ  c 
degradation and signiﬁ  cant storage time dependent 
under-representation within the PAXgene
TM sam-
ples are therefore undetermined at this time.
Our data are concordant with several reports 
that RNA integrity remains intact following 
extended room temperature storage times follow-
ing PAXgene
TM blood sample collection (Chai 
et al. 2005; Thach et al. 2003; Wang et al. 2004). 
However, we have shown degradation and sig-
niﬁ  cant under-representation of a large number of 
transcripts following just 24 hrs room temperature 
storage, supporting previous reports (Kagedal et al. 
2005) of sample instability, but contrary to others 
showing no change in transcript levels up to 5 days 
of room temperature storage (Chai et al. 2005). It 
is likely that this latter discrepancy is due to the 
use of qPCR methods to analyse only a small 
number of speciﬁ  c transcripts (Chai et al. 2005; 
Thach et al. 2003; Wang et al. 2004), rather than 
global proﬁ  ling approaches. Reports have also 
compared longer storage times (24 hrs and 5 days) 
demonstrating no alterations in transcript repre-
sentation (Chai et al. 2005). However, with the 
omission of shorter time points interpretation of 
whether the abundance of these transcripts has 
already altered from their original basal levels at 
time of collection is not possible.
We report the generation of high quality global 
gene expression data from PAXgene
TM peripheral 
blood samples, which we believe will be vital for 
future biomarker discovery and interrogation 
within clinical samples. However, considering 
transcriptome alterations observed within the stor-
age time range recommended by the manufacturers 
it will be imperative to instigate a ﬁ  xed storage 
time for all clinical samples intended for direct 
comparison within a given study.
A further aim of this study was to assess the 
suitability of a single-primer isothermal linear 
ampliﬁ  cation (SPIA) method for application with 
Affymetrix GeneChip microarrays for whole blood 
transcriptome analysis potentially mitigating the 
need for globin reduction. Globin reduction prac-
tices in whole blood RNA sample processing have 
previously been shown to alter global gene 
expression proﬁ  les obtained (Feezor et al. 2004; 
Liu et al. 2006) and signiﬁ  cantly increase sample 
handling. Using this SPIA technology we synthe-
sised high quality sscDNA in ample quantity from 
PAXgene
TM samples to carry out hybridisation to 
microarrays. sscDNA probes for microarrays have 
previously been shown to provide high speciﬁ  city 416
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of hybridisation and consequently provide 
increased percentage present calls, as a result of 
reduced cross-hybridisation to mismatch control 
probes, and with this workﬂ  ow we achieved a 
minimum of 60 percent present calls on Affymetrix 
Genechips. Therefore, we have demonstrated that 
NuGEN Technologies Whole Blood Ovation
TM 
RNA ampliﬁ  cation for probe generation permits 
analysis of gene expression proﬁ  les from whole 
blood with minimal handling steps without the 
requirement for potentially transcriptome-modify-
ing globin reduction practices that were previously 
required and recommended by the Best Practices 
Blood Handling for Array Based Expression Work-
ing Group (www.affymetrix.com/community/stan-
dards/blood_protocol.affx). Importantly, the gene 
expression data sets obtained as a result of this 
workflow result in excellent representation of 
individual hematopoietic cell lineages with a wide 
spectrum of transcript abundances, thereby sup-
porting the notion that efficient whole blood 
expression proﬁ  ling studies can be achieved with-
out requirement for lineage or cell population 
enrichment strategies and without loss of data 
contributed by speciﬁ  c lineages. Whilst the high 
levels of representation of transcripts indicative of 
speciﬁ  c cell lineages in the PAXgene
TM / sscDNA 
dataset was remarkable, as expected several of 
these did not reach 100% and we consider this a 
likely reﬂ  ection of the methods employed for indi-
vidual lineage enrichment. Notably, those lineages 
with lowest representation (approximately 70%) 
result from enrichment schemes which include 
subsequent in vitro stimulation and culture and 
with transcriptome proﬁ  les likely least reﬂ  ective 
of those lineages in vivo.
We conclude that robust global gene expression 
proﬁ  ling from whole blood without the require-
ment for globin reduction processing schemes and 
with maximal representation of individual hema-
topoietic lineages can be achieved by combination 
of PAXgene
TM RNA stabilisation procedures, albeit 
with careful consideration to fixed incubation 
periods for all samples within a clinical collection, 
together with NuGEN Technologies Whole 
Blood Ovation
TM RNA ampliﬁ  cation system for 
microarray probe generation.
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